Editas Medicine (EDIT) News Today $3.16 -0.12 (-3.66%) (As of 02:25 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 EPS Estimates for Editas Medicine Raised by AnalystEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Leerink Partnrs raised their FY2024 EPS estimates for Editas Medicine in a note issued to investors on Monday, November 4th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($2.81) per shareNovember 7 at 7:28 AM | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $7.00 by Analysts at Wells Fargo & CompanyNovember 7 at 4:43 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from BrokeragesNovember 7 at 2:15 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seven haNovember 7 at 2:14 AM | marketbeat.comGrowth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%November 6 at 4:49 PM | finance.yahoo.comEditas Medicine upgraded to Outperform from In Line at Evercore ISINovember 6 at 4:49 PM | markets.businessinsider.comEditas Medicine Downgraded by Raymond James Amid Strategic Shift and Program UncertaintyNovember 6 at 11:47 AM | finance.yahoo.comEditas Medicine’s Strong Financial Position and Promising Clinical Progress Drive Buy RatingNovember 6 at 11:47 AM | markets.businessinsider.comEditas Medicine to Participate in Upcoming Investor ConferencesNovember 6 at 9:00 AM | globenewswire.comChardan Capital Reiterates Buy Rating for Editas Medicine (NASDAQ:EDIT)Chardan Capital reaffirmed a "buy" rating and issued a $12.00 target price on shares of Editas Medicine in a report on Tuesday.November 5 at 5:40 PM | marketbeat.comEditas Medicine (NASDAQ:EDIT) Price Target Cut to $5.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada lowered their target price on Editas Medicine from $8.00 to $5.00 and set a "sector perform" rating on the stock in a report on Tuesday.November 5 at 11:39 AM | marketbeat.comEditas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings ResultsEditas Medicine (NASDAQ:EDIT - Get Free Report) released its earnings results on Monday. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.75). Editas Medicine had a negative return on equity of 62.61% and a negative net margin of 288.59%. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $3.93 million. During the same quarter in the previous year, the business earned ($0.55) earnings per share. Editas Medicine's quarterly revenue was down 98.9% on a year-over-year basis.November 5 at 8:48 AM | marketbeat.comEditas Medicine Third Quarter 2024 Earnings: Misses ExpectationsNovember 5 at 8:08 AM | finance.yahoo.comEditas Medicine Reports Q3 2024 Results and DevelopmentsNovember 5 at 3:07 AM | markets.businessinsider.comEditas downgraded to market perform by Raymond JamesNovember 4 at 6:44 PM | msn.comEditas Medicine downgraded to Market Perform from Outperform at Raymond JamesNovember 4 at 6:44 PM | markets.businessinsider.comEditas Medicine: Strong Cash Position and Strategic Focus on Innovative Gene Editing Programs Drive Buy RatingNovember 4 at 6:44 PM | markets.businessinsider.comEditas Medicine (NASDAQ:EDIT) Stock Rating Lowered by Raymond JamesRaymond James lowered Editas Medicine from an "outperform" rating to a "market perform" rating in a report on Monday.November 4 at 1:30 PM | marketbeat.comEditas Medicine Announces Third Quarter 2024 Results and Business UpdatesNovember 4 at 7:30 AM | globenewswire.comIs Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?November 1, 2024 | msn.comEditas Medicine, Inc. (NASDAQ:EDIT) Short Interest UpdateEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) was the target of a significant growth in short interest in October. As of October 15th, there was short interest totalling 18,330,000 shares, a growth of 9.5% from the September 30th total of 16,740,000 shares. Based on an average daily volume of 1,860,000 shares, the short-interest ratio is currently 9.9 days.October 30, 2024 | marketbeat.comChardan Capital Predicts Higher Earnings for Editas MedicineOctober 28, 2024 | americanbankingnews.comChardan Capital Comments on Editas Medicine FY2024 EarningsEditas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Analysts at Chardan Capital increased their FY2024 EPS estimates for Editas Medicine in a research note issued to investors on Wednesday, October 23rd. Chardan Capital analyst Y. Livshits now expects that the company will post earnings of ($2.58October 28, 2024 | marketbeat.comEditas Medicine: Balancing Strategic Shifts and Uncertainties with a Hold RatingOctober 25, 2024 | markets.businessinsider.comEditas Medicine: Strategic Shift Towards In Vivo Technologies and Long-term Growth PotentialOctober 25, 2024 | markets.businessinsider.comStrategic Shift and Promising Data Boost Buy Rating for Editas MedicineOctober 24, 2024 | markets.businessinsider.comCautious Hold on Editas Medicine Amid Strategic Shifts and Financial UncertaintiesOctober 24, 2024 | markets.businessinsider.comEditas Medicine (EDIT) Gets a Hold from OppenheimerOctober 24, 2024 | markets.businessinsider.comEditas Medicine (EDIT) Gets a Buy from Truist FinancialOctober 24, 2024 | markets.businessinsider.comEvercore ISI Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00Evercore ISI decreased their price target on shares of Editas Medicine from $7.00 to $3.00 and set an "in-line" rating for the company in a research report on Wednesday.October 23, 2024 | marketbeat.comEditas Medicine price target lowered to $10 from $18 at BairdOctober 23, 2024 | markets.businessinsider.comEditas Medicine price target lowered to $12 from $20 at ChardanOctober 23, 2024 | markets.businessinsider.comChardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $12.00Chardan Capital reduced their price target on shares of Editas Medicine from $20.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday.October 22, 2024 | marketbeat.comEditas Medicine, Genevant Sciences enter collaboration and license agreementOctober 22, 2024 | markets.businessinsider.comEditas Medicine, Inc. (EDIT) Strategic Update Call TranscriptOctober 22, 2024 | seekingalpha.comEditas Medicine, Inc.: Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing TherapeuticsOctober 22, 2024 | finanznachrichten.deEditas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic UpdateOctober 22, 2024 | markets.businessinsider.comEditas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing TherapeuticsOctober 21, 2024 | globenewswire.comEditas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of ConceptOctober 18, 2024 | globenewswire.comState Street Corp's Strategic Reduction in Editas Medicine Inc HoldingsOctober 17, 2024 | finance.yahoo.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Large Decrease in Short InterestEditas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 16,740,000 shares, a decrease of 11.7% from the September 15th total of 18,960,000 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is presently 9.3 days.October 15, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) Given Average Recommendation of "Hold" by AnalystsShares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given a consensus recommendation of "Hold" by the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold rating and three have assigned a buy ratingOctober 13, 2024 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) is largely controlled by institutional shareholders who own 64% of the companyOctober 12, 2024 | finance.yahoo.comRenaissance Technologies LLC Reduces Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)Renaissance Technologies LLC cut its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 89.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 98,429 shares of the company's stock afterOctober 11, 2024 | marketbeat.comEditas Medicine (NASDAQ:EDIT) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comMillennium Management LLC Has $11.49 Million Stock Position in Editas Medicine, Inc. (NASDAQ:EDIT)Millennium Management LLC raised its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 10.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,459,629 shares of the compOctober 8, 2024 | marketbeat.comWells Fargo Sticks to Their Buy Rating for Editas Medicine (EDIT)October 7, 2024 | markets.businessinsider.comEditas Medicine (EDIT) Shares Plunge Amid Biotech Sector FluctuationsOctober 7, 2024 | gurufocus.comEditas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Dimensional Fund Advisors LPDimensional Fund Advisors LP lowered its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 10.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,345,054 shares ofOctober 7, 2024 | marketbeat.comEditas Medicine Secures $57M Deal for Gene-Editing TechnologyOctober 5, 2024 | finance.yahoo.com Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future. To claim your copy, follow this link EDIT Media Mentions By Week EDIT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EDIT News Sentiment▼0.030.38▲Average Medical News Sentiment EDIT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EDIT Articles This Week▼304▲EDIT Articles Average Week Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Adverum Biotechnologies News Today Cellectis News Today Sangamo Therapeutics News Today REGENXBIO News Today Precision BioSciences News Today bluebird bio News Today Arcutis Biotherapeutics News Today Applied Therapeutics News Today Prothena News Today Cullinan Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EDIT) was last updated on 11/7/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
